Okay thanks a lot for the opportunity ma'am. Harshit Dhoot from Dymon Asia Capital. Just one bookkeeping question. Our EBITDA of INR700 crores in biosimilars business, is there any inclusion of the exceptional gain, which we have put in the notes to accounts in this INR 700 crore number?
So, INR 700 crores is the clean EBITDA, Kedar?
Hi, first of all, congratulations to Subbu sir and the Aurobindo Pharma management team for the MIP on the Pen -G part. Sir, just one help which I wanted on the modelling purpose. We have got the MIP at $25 for Pen -G. But sir, if you do the calculation, the two Pen-G equals to one 6-APA, and most of the formulation plants source 6 -APA or the Amoxicillin, where the prices are similar to the market. So from the modelling purpose, should we take the prices at $25 per kg, or we should reduce it down keeping in line to the ratio and MIP that we got on the Amoxicillin and the 6-APA?
The consumers are saying that we should buy Amoxicillin…